FDA approves Ocrelizumab for relapsing-remitting and primary progressive MS
April 3, 2017The American Food and Drug Administration (FDA) has approved OCREVUS™ (ocrelizumab) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. To read more, click on the link below:
FDA approves Ocrelizumab for relapsing-remitting and primary progressive MS
Article courtesy of MS Research Australia www.msra.org.au